[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Società Italiana di Allergologia, Asma e Immunologia Clinica\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100564134","severe-asthma-network-italy-100564134",false,"NCT06625216","Severe Asthma Network Italy","Observatory of Patients With Severe Asthma and Potential Eligible Patients for Treatment With Biological Drugs","SANI","Inclusion Criteria:\n\n1. signed informed consent and privacy disclaimer;\n2. age \\> 12 years;\n3. diagnosis of severe asthma according to the ERS\u002FATS criteria:\n\n   1. During treatment with:\n\n      * High-dose ICS + at least one addistional controller (LABA, montelukast, or theophylline) or\n      * Oral corticosteroids \\>6 months\u002Fyear\n   2. at least one of the following occurs or would occur if treatment would be reduced:\n\n      * ACT \\\u003C20 or ACQ\\>1.5\n      * At least 2 exacerbations in the last 12 months\n      * At least 1 exacerbation treated in hospital or requiring mechanical ventilation in the last 12 months\n      * FEV1 \\\u003C80% (if FEV1\u002FFVC below the lower limit of normal)\n\nExclusion Criteria have not been considered in order to have a realistic view of severe asthma in real life.","ALL","13 Years",{"count":20,"type":21},5000,"ESTIMATED","OBSERVATIONAL","The goal of this registry is collecting data of severe asthma patients, recruited by specialized centers, in a real life setting, homogeneously placed on a database management system to follow them over the time.\n\nThe information recorded will provide:\n\n1. The collection of homogeneous clinical, functional and biologic data of patients with severe asthma in a real life setting.\n2. The evaluation of adherence to treatment in real life.\n3. The clinical eligibility of patients treated with biologics.\n4. The evaluation of patients' clinical response to each treatment.\n5. The monitoring of tolerability and safety.\n6. The long-term follow up of patients with severe asthma.",[25],"Severe Asthma",[25,27,28,29,30],"Network","Registry","Biologics","Adherence","RECRUITING","2026-04-23",{"date":34,"type":35},"2026-04-29","ACTUAL",{"date":37,"type":35},"2017-02-17",{"date":39,"type":21},"2037-02-17",{"name":41,"class":42},"Società Italiana di Allergologia, Asma e Immunologia Clinica","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100606442","lupus-eritematoso-sistemico-network-and-registry-100606442","NCT07175610","LUpus Eritematoso Sistemico NETwork and Registry","The LUNET Project: the Italian Systemic Erythematous Lupus Network and Registry","LUNET","Inclusion Criteria:\n\n* age ≥ 18 years;\n* confirmed SLE diagnosis according to the SLICC 2012 and\u002For ACR\u002FEULAR 2019 classification criteria;\n* provision of signed written informed consent prior to participation\n\nExclusion Criteria:\n\n\\-","18 Years",{"count":54,"type":21},1500,"10 Years","The LUNET Registry is intended to serve as a comprehensive primary data source, capturing real-world longitudinal clinical information, and the heterogeneity of patient presentations that are often underrepresented in traditional clinical trials. Ultimately, the LUNET Registry will help to optimize SLE management in routine clinical practice by enabling the compilation of real-world evidence to inform clinical decision-making and health policy. Patients will be enrolled by secondary and tertiary care centres for SLE across Italy in a real-world clinical set-up.",[58],"Systemic Lupus Erythematous (SLE)",[60,61,62,63,64],"Systemic Erythematosus Lupus","Connective Tissue Diseases","Autoimmune Diseases","mmune System Diseases","Biologic Therapies","NOT_YET_RECRUITING","2025-09-09",{"date":68,"type":35},"2025-09-16",{"date":70,"type":21},"2025-09-30",{"date":72,"type":21},"2035-12-31",{"name":41,"class":42},16,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":55,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":94,"locationsCount":95},"100554468","italian-registry-of-allergen-immunotherapy-100554468","NCT06499480","Italian Registry of Allergen ImmunoTherapy","Italian Registry of Patients With Allergic Disease and Treated With Allergen ImmunoTherapy","RIAIT","Inclusion Criteria:\n\n* Age ≥ 1 year\n* Confirmed diagnosis of allergic rhinoconjunctivitis and\u002For allergic asthma according to EAACI 2019 guidelines.\n* Having been followed by the recruiting center for at least one month: this is considered necessary to establish that the patients are truly affected by allergic respiratory disease and are eligible for allergen-specific immunotherapy; in this period, screening tests are carried out to exclude and\u002For confirm concomitant diseases (comorbidities). In fact, according to the aforementioned EAACI guidelines, a patient can be defined as truly eligible for allergen-specific immunotherapy only after a preliminary phase in which the patient is treated with symptomatic therapy; this observation period allows a correct evaluation of the real adherence and response to therapy, as well as the identification and appropriate treatment of any comorbidity and the possible elimination of aggravating factors.\n* Having received the prescription of any of the available AIT products in Italy, irrespectively of the selected allergens and the administration route and schedule.\n\nExclusion Criteria:\n\nThere will no be exclusion criteria, in order to allow a real-life vision of the characteristics of these patients eligible for or treated with allergen-specific immunotherapy.","1 Year",{"count":20,"type":21},"RIAIT (Italian Registry of Allergy Immunotherapy) is a multicenter observational study that aims to prospectively collect the most extensive data available on Italian patients using AIT for respiratory allergies (rhinoconjunctivitis and\u002For asthma) in a real-life context, through a network of allergy centers with specific interest and expertise in the management of allergic respiratory patients.",[87],"Allergic Respiratory Disease","2025-03-03",{"date":90,"type":35},"2025-03-06",{"date":92,"type":35},"2024-05-01",{"date":72,"type":21},{"name":41,"class":42},2,""]